Jeonju

Running trials

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· Source

• Recruiting

  Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

  NCT05952024· Phase 2· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· Source

• Active, not recruiting

  A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

  NCT04529772· Phase 3· Source

• Active, not recruiting

  A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD2 recruiting
• Diffuse large B-cell lymphoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· Source

• Completed

  A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

  NCT06075095· Phase 3· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· Source

• Completed

  A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

  NCT05755906· Phase 3· Source

• Completed

  Dapagliflozin Post Marketing Surveillance in HF and CKD

  NCT05134701· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· Source

• Completed

  QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

  NCT05160974· Source

• Terminated

  Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

  NCT05006573· Phase 3· Source

• Completed

  'OLAP' (OLAparib Regulatory Post-marketing Surveillance)

  NCT04553926· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· Source

• Completed

  Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

  NCT04068168· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· Source

• Completed

  Tezepelumab COPD Exacerbation Study

  NCT04039113· Phase 2· Source

• Completed

  Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

  NCT03927157· Phase 3· Source